News Sentiment

DYAI sentiment intelligence

Dyadic International Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 60 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.06 Week of 10 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

78/100 classification confidence.

Company focus 52

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+12.7% over one week, +55.4% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

Price to sales forward of Dyadic International, Inc. – NASDAQ:DYAI

Market Reaction

Price moving ahead of tone

64/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 78/100 classification
One-week reaction 12.7% Price confirming higher
Trend fit Trend inactive 55.4% over four weeks
Fair value -18.5% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 19
Neutral 38
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 52
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
GlobeNewswire 12
Stock Titan 11
Market source 5
AD HOC NEWS 4
simplywall.st 3
TradingView 2
MT Newswires 2
Finviz 2

Event Lens

What the news is about

Classified themes
Market update 30
Earnings 23
Deals and strategy 4
Analyst action 2
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 60
TipRanks Direct company coverage

Dyadic International’s Earnings Call Shows Early Momentum

Dyadic International (DYAI) reported a significant 182% year-over-year revenue increase in Q1 2026, reaching $1.1 million, driven by R&D, grant, and milestone revenues. The company announced several commercial product launches and expanded partnerships, while also demonstrating c

Tone
Neutral 50/100
Event
Earnings
Published
20 May 2026 18:40
Source
TipRanks
Investing.com Direct company coverage

Earnings call transcript: Dyadic’s Q1 2026 revenue surges 182% despite EPS miss

Dyadic International Inc. reported a 182% increase in Q1 2026 revenue, reaching $1.1 million, despite an EPS loss of $0.05, meeting analyst forecasts. The stock, however, saw a 4.54% decline in after-hours trading due to investor concerns over operational losses and increased adm

Tone
Neutral 50/100
Event
Earnings
Published
20 May 2026 14:10
Source
Investing.com
AD HOC NEWS Direct company coverage

Dyadic International stock (US26746E1055): Shares climb after recent momentum

Dyadic International's shares (US26746E1055) recently climbed 5.07%, drawing attention to the small-cap biotechnology firm. This gain is attributed to renewed market momentum rather than a specific corporate announcement, highlighting the stock's sensitivity to sentiment and limi

Tone
Positive 67/100
Event
Market update
Published
16 May 2026 18:28
Source
AD HOC NEWS
The Globe and Mail Direct company coverage

Dyadic International Earnings Call Highlights Early Momentum

Dyadic International's Q1 earnings call revealed significant year-over-year revenue growth and several new product launches, signaling early commercialization momentum, particularly in biopharma, food, and bioindustrial markets. Despite improved operating losses and a solid cash

Tone
Positive 65/100
Event
Earnings
Published
15 May 2026 03:09
Source
The Globe and Mail
Investing.com India Direct company coverage

Earnings call transcript: Dyadic International Q1 2026 revenue beats forecast, stock dips By Investing.com

Dyadic International (DYAI) reported Q1 2026 revenue of $1.11 million, exceeding forecasts by 3.74%, while EPS met expectations at -$0.05. Despite the revenue beat and significant year-over-year growth, the stock dipped 1.8% in aftermarket trading due to ongoing operational losse

Tone
Neutral 50/100
Event
Earnings
Published
14 May 2026 15:09
Source
Investing.com India
Stock Titan Direct company coverage

Dyadic International (NASDAQ: DYAI) grows Q1 2026 revenue but flags going-concern risks

Dyadic International (NASDAQ: DYAI) reported a significant increase in Q1 2026 revenue to $1.11 million, up from $393,572, driven by research collaborations, grants, and license milestones. Despite this growth and a slightly narrowed net loss of $1.95 million, the company faces s

Tone
Neutral 50/100
Event
Earnings
Published
13 May 2026 20:38
Source
Stock Titan
GlobeNewswire Direct company coverage

Dyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics and Vaccines Using its Proprietary C1 Cell Microbial Protein Production Platform

Dyadic International, Inc. has announced a strategic partnership with Rabian BV to develop affordable rabies prophylactics and vaccines using Dyadic's proprietary C1 protein production platform. This collaboration, partially funded by Eurostars, aims to address the global burden

Tone
Positive 70/100
Event
Deals and strategy
Published
27 Apr 2026 19:40
Source
GlobeNewswire
AD HOC NEWS Direct company coverage

Dyadic International stock (US26746E1055): Is its biotech platform strong enough to unlock new upside?

Dyadic International leverages its C1 platform, a genetically engineered fungus, to produce biologics faster and cheaper than traditional methods, targeting the biopharmaceutical industry's need for efficient manufacturing. The company operates through licensing deals and collabo

Tone
Positive 66/100
Event
Market update
Published
21 Apr 2026 04:25
Source
AD HOC NEWS
AD HOC NEWS Direct company coverage

Dyadic International Stock: Biotechnology Innovator Focused on C1 Platform Amid Earnings Challenges

Dyadic International is a Florida-based biotech firm leveraging its proprietary C1 fungal-based expression platform for scalable protein production across biopharmaceuticals, industrial enzymes, and agricultural bioactives. Despite ongoing losses and recent earnings challenges, t

Tone
Neutral 50/100
Event
Earnings
Published
02 Apr 2026 17:40
Source
AD HOC NEWS
Simply Wall Street Direct company coverage

Dyadic International, Inc.'s (NASDAQ:DYAI) Path To Profitability

Dyadic International, Inc. (NASDAQ:DYAI), a biotechnology platform company with a US$25m market cap, is projected by analysts to break even by 2027, turning a profit of US$1.9m after a final loss in 2026. This aggressive growth forecast of 121% year-on-year raises questions about

Tone
Neutral 50/100
Event
Earnings
Published
28 Mar 2026 07:39
Source
Simply Wall Street
The Globe and Mail Direct company coverage

Dyadic (DYAI) Q4 2025 Earnings Call Transcript

Dyadic International (DYAI) reported a shift from a development-stage company to a commercial-stage biotechnology business in Q4 2025. The company launched its first commercial products, secured strategic partnerships, and began generating recurring revenue streams. Despite a net

Tone
Positive 67/100
Event
Earnings
Published
25 Mar 2026 17:23
Source
The Globe and Mail
Investing.com Canada Direct company coverage

Dyadic International Inc (DYAI) Q4 2025 Earnings Call Highlights: Navigating Transition with ... By GuruFocus

Dyadic International Inc. (DYAI) reported its Q4 2025 earnings, highlighting a transition from a development-stage company to a commercial product-driven biotechnology business. Despite a decrease in total revenue to $3.09 million and an increased net loss of $7.36 million, the c

Tone
Neutral 50/100
Event
Earnings
Published
25 Mar 2026 17:00
Source
Investing.com Canada
GlobeNewswire Direct company coverage

Dyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT Bioservices

Dyadic Applied BioSolutions has entered into an OEM distribution agreement with IBT Bioservices to commercialize its recombinant protein products. This partnership will utilize IBT's established sales channels, primarily focusing on recombinant DNase I and transferrin for researc

Tone
Positive 71/100
Event
Deals and strategy
Published
17 Mar 2026 04:09
Source
GlobeNewswire
The Manila Times Direct company coverage

Dyadic to Report 2025 Full Year Financial Results and Host Conference Call on Wednesday, March 25, 2026

Dyadic International, Inc. will report its financial results for the year ended December 31, 2025, and host a corporate update conference call on Wednesday, March 25, 2026, at 5:00 p.m. Eastern Time. The biotechnology company, known for its proprietary gene expression platforms,

Tone
Neutral 50/100
Event
Earnings
Published
15 Mar 2026 10:39
Source
The Manila Times
Stock Titan Direct company coverage

Dyadic to detail full-year 2025 results in March 25 investor call

Dyadic (Nasdaq: DYAI) announced it will report its full-year 2025 financial results and host a corporate update conference call on Wednesday, March 25, 2026, at 5:00 p.m. ET. Investors can join via dial-in or live webcast, with an archive available afterward on the company's Inve

Tone
Neutral 50/100
Event
Earnings
Published
10 Mar 2026 11:39
Source
Stock Titan
Stock Titan Direct company coverage

Animal-free enzyme from Dyadic and Fermbox targets gene therapy

Dyadic Applied BioSolutions (NASDAQ: DYAI) and Fermbox Bio have launched their first commercial product under an expanded collaboration: an animal-origin-free Recombinant DNase I (RNase-free). This enzyme, currently available in research grade with a cGMP-grade version in develop

Tone
Positive 67/100
Event
Market update
Published
07 Mar 2026 17:08
Source
Stock Titan
GlobeNewswire Direct company coverage

Dyadic and Fermbox Bio Launch First Product Under Expanded Collaboration: Animal-Origin-Free Recombinant DNase I (RNase-Free)

Dyadic Applied BioSolutions and Fermbox Bio have launched their first commercial product, animal-origin-free Recombinant DNase I (RNase-free), under their expanded collaboration. This marks a significant step for Dyadic in transitioning towards commercial product expansion and re

Tone
Positive 82/100
Event
Market update
Published
04 Mar 2026 07:20
Source
GlobeNewswire
GlobeNewswire Direct company coverage

Dyadic and Fermbox Bio Launch First Product Under Expanded

Dyadic Applied BioSolutions and Fermbox Bio have launched their first commercial product, animal-origin-free Recombinant DNase I (RNase-free), under their expanded collaboration. This product, developed using Dyadic's microbial expression platforms and Fermbox Bio's biomanufactur

Tone
Positive 72/100
Event
Market update
Published
04 Mar 2026 07:20
Source
GlobeNewswire
GlobeNewswire Direct company coverage

Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development Milestone

Dyadic Applied BioSolutions and Inzymes ApS have announced the planned 2026 commercialization of recombinant non-animal bovine chymosin, a key enzyme for cheese production, after successfully completing final development activities. The achievement of this milestone earned Dyadic

Tone
Positive 74/100
Event
Market update
Published
02 Mar 2026 18:51
Source
GlobeNewswire
Stock Titan Direct company coverage

Animal-free cheese enzyme set for 2026 launch in $2B dairy market

Dyadic Applied BioSolutions and Inzymes ApS have announced the planned 2026 commercialization of recombinant non-animal bovine chymosin for cheese production, a key enzyme in the $1.5-2.0 billion global dairy processing enzyme market. This follows the successful completion of dev

Tone
Positive 74/100
Event
Market update
Published
02 Mar 2026 11:51
Source
Stock Titan